United Therapeutics Co. (NASDAQ:UTHR) Receives $388.25 Consensus Price Target from Brokerages

Shares of United Therapeutics Co. (NASDAQ:UTHR) have received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $388.25.

Several equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th.

United Therapeutics Trading Down 0.2 %

United Therapeutics stock opened at $312.99 on Friday. The firm has a 50-day moving average price of $345.10 and a 200-day moving average price of $356.99. The firm has a market capitalization of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 EPS. As a group, sell-side analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,255 shares of company stock valued at $32,614,521. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wealthfront Advisers LLC grew its position in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. boosted its stake in United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock worth $1,567,253,000 after purchasing an additional 32,213 shares in the last quarter. FMR LLC boosted its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Geode Capital Management LLC boosted its stake in United Therapeutics by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after purchasing an additional 44,277 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after purchasing an additional 7,710 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.